KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opko Health (OPK) Cash & Equivalents (2016 - 2026)

Opko Health filings provide 17 years of Cash & Equivalents readings, the most recent being $341.9 million for Q1 2026.

  • On a quarterly basis, Cash & Equivalents fell 21.59% to $341.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was $341.9 million, a 21.59% decrease, with the full-year FY2025 number at $369.1 million, down 14.55% from a year prior.
  • Cash & Equivalents hit $341.9 million in Q1 2026 for Opko Health, down from $369.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $436.0 million in Q1 2025 to a low of $40.6 million in Q2 2024.
  • Median Cash & Equivalents over the past 5 years was $180.8 million (2022), compared with a mean of $228.7 million.
  • Biggest five-year swings in Cash & Equivalents: plummeted 62.47% in 2024 and later skyrocketed 569.65% in 2025.
  • Opko Health's Cash & Equivalents stood at $153.2 million in 2022, then plummeted by 37.41% to $95.9 million in 2023, then surged by 350.49% to $431.9 million in 2024, then fell by 14.55% to $369.1 million in 2025, then fell by 7.37% to $341.9 million in 2026.
  • The last three reported values for Cash & Equivalents were $341.9 million (Q1 2026), $369.1 million (Q4 2025), and $415.2 million (Q3 2025) per Business Quant data.